Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Three Phase III Trials Ongoing In Three Other Indications
Mar 21 2024
•
By
Mandy Jackson
The myasthenia gravis pharma market is growing despite some setbacks • Source: Shutterstock
More from Clinical Trials
More from R&D